6-[4-[[[3-(2-Aminophenyl)-3-oxopropyl]amino]methyl]phenyl]-5-phenylpyridine-3-carbonitrile | 790659-94-8

• 分子结构分类: 有机化合物 - 有机氧化合物
• 英文名称: 6-[4-[[[3-(2-Aminophenyl)-3-oxopropyl]amino]methyl]phenyl]-5-phenylpyridine-3-carbonitrile
• 英文别名: 6-[4-[[[3-(2-aminophenyl)-3-oxopropyl]amino]methyl]phenyl]-5-phenylpyridine-3-carbonitrile
• CAS: 790659-94-8
• 化学式: C₂₈H₂₄N₄O
• 分子量: 432.525
• InChiKey: FDVSGRHYXFOPPL-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4.4
• 重原子数：
  33
• 可旋转键数：
  8
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.11
• 拓扑面积：
  91.8
• 氢给体数：
  2
• 氢受体数：
  5

反应信息

• 作为反应物：
  描述：

  6-[4-[[[3-(2-Aminophenyl)-3-oxopropyl]amino]methyl]phenyl]-5-phenylpyridine-3-carbonitrile 、 氨基硫脲 在 三氟乙酸 作用下， 反应 16.0h， 生成 1-(2-Aminophenyl)-3-({4-[5-(5-amino-1,3,4-thiadiazol-2-yl)-3-phenylpyridin-2-yl]benzyl}amino)propan-1-one
  参考文献：
  名称：

  Optimization of 2,3,5-trisubstituted pyridine derivatives as potent allosteric Akt1 and Akt2 inhibitors

  摘要：

  This letter shows inhibitor SAR on a pyridine series of allosteric Akt inhibitors to optimize enzymatic and cellular potency. We have optimized 2,3,5-trisubstituted pyridines to give potent Akt1 and Akt2 inhibitors in both enzyme and cell based assays. In addition, we will also highlight the pharmacokinetic pro. le of an optimized inhibitor that has low clearance and long half-life in dogs. (C) 2007 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2007.12.040
• 作为产物：
  描述：

  6-[4-(Bromomethyl)phenyl]-5-phenylnicotinonitrile 、 3-氨基-1-(2-氨基苯基)-丙酮 在 N,N-二异丙基乙胺 作用下， 以 四氢呋喃 、 甲醇 为溶剂， 反应 1.0h， 生成 6-[4-[[[3-(2-Aminophenyl)-3-oxopropyl]amino]methyl]phenyl]-5-phenylpyridine-3-carbonitrile
  参考文献：
  名称：

  Optimization of 2,3,5-trisubstituted pyridine derivatives as potent allosteric Akt1 and Akt2 inhibitors

  摘要：

  This letter shows inhibitor SAR on a pyridine series of allosteric Akt inhibitors to optimize enzymatic and cellular potency. We have optimized 2,3,5-trisubstituted pyridines to give potent Akt1 and Akt2 inhibitors in both enzyme and cell based assays. In addition, we will also highlight the pharmacokinetic pro. le of an optimized inhibitor that has low clearance and long half-life in dogs. (C) 2007 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2007.12.040

文献信息

• INHIBITORS OF AKT ACTIVITY
  申请人：Merck & Co., Inc.

  公开号：EP1631548B1

  公开（公告）日：2009-10-28
• US7414055B2
  申请人：——

  公开号：US7414055B2

  公开（公告）日：2008-08-19
• Optimization of 2,3,5-trisubstituted pyridine derivatives as potent allosteric Akt1 and Akt2 inhibitors
  作者：John C. Hartnett、Stanley F. Barnett、Mark T. Bilodeau、Deborah Defeo-Jones、George D. Hartman、Hans E. Huber、Raymond E. Jones、Astrid M. Kral、Ronald G. Robinson、Zhicai Wu

  DOI：10.1016/j.bmcl.2007.12.040

  日期：2008.3

  This letter shows inhibitor SAR on a pyridine series of allosteric Akt inhibitors to optimize enzymatic and cellular potency. We have optimized 2,3,5-trisubstituted pyridines to give potent Akt1 and Akt2 inhibitors in both enzyme and cell based assays. In addition, we will also highlight the pharmacokinetic pro. le of an optimized inhibitor that has low clearance and long half-life in dogs. (C) 2007 Elsevier Ltd. All rights reserved.